Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Depreciation & Amortization (CF) (2022 - 2025)

Envoy Medical's Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $76000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 55.1% year-over-year to $76000.0; the TTM value through Sep 2025 reached $270000.0, up 92.86%, while the annual FY2024 figure was $173000.0, 73.0% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $76000.0 at Envoy Medical, down from $85000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $85000.0 in Q2 2025 and bottomed at $15000.0 in Q4 2023.
  • The 4-year median for Depreciation & Amortization (CF) is $38000.0 (2024), against an average of $43416.7.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 42.31% in 2023 before it surged 220.0% in 2024.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $26000.0 in 2022, then plummeted by 42.31% to $15000.0 in 2023, then soared by 220.0% to $48000.0 in 2024, then surged by 58.33% to $76000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Depreciation & Amortization (CF) are $76000.0 (Q3 2025), $85000.0 (Q2 2025), and $61000.0 (Q1 2025).